Abstract
The in vitro insulin unfolding had been studied using the “equilibrium unfolding” method where protein is unfolded by reducing reagents in the presence of trace amounts of oxidants such as oxidized glutathione. Nine intermediates were captured in the unfolding process, named as P1A, P2A, P3A, P4A, P3B, P4B, P5B, P6B, and P7B, which were all either A chain derivatives or B chain derivatives. No intermediate with inter-A-B chain disulfide was captured. Based on the character of the intermediates, their distribution during the unfolding process and the hypothetic “transient” intermediates, an in vitro putative unfolding pathway of insulin had been proposed. Besides, the comparison of the intermediates captured in unfolding with the intermediates captured in the refolding process of insulin revealed that both unfolding/ refolding processes of insulin shared common intermediates. Based on these observations we suggested that the unfolding pathway of insulin was similar to the refolding pathway but flowed in the opposite direction.
Keywords: Disulfide, folding, insulin, unfolding, unfolding intermediate, unfolding pathway
Protein & Peptide Letters
Title: In Vitro Unfolding of Insulin: Characterization of Intermediates and Putative Unfolding Pathway
Volume: 17 Issue: 7
Author(s): Jie Zhao, Qi-Long Huang, Yue-Hua Tang, Fu-Kun Zhao and You-Min Feng
Affiliation:
Keywords: Disulfide, folding, insulin, unfolding, unfolding intermediate, unfolding pathway
Abstract: The in vitro insulin unfolding had been studied using the “equilibrium unfolding” method where protein is unfolded by reducing reagents in the presence of trace amounts of oxidants such as oxidized glutathione. Nine intermediates were captured in the unfolding process, named as P1A, P2A, P3A, P4A, P3B, P4B, P5B, P6B, and P7B, which were all either A chain derivatives or B chain derivatives. No intermediate with inter-A-B chain disulfide was captured. Based on the character of the intermediates, their distribution during the unfolding process and the hypothetic “transient” intermediates, an in vitro putative unfolding pathway of insulin had been proposed. Besides, the comparison of the intermediates captured in unfolding with the intermediates captured in the refolding process of insulin revealed that both unfolding/ refolding processes of insulin shared common intermediates. Based on these observations we suggested that the unfolding pathway of insulin was similar to the refolding pathway but flowed in the opposite direction.
Export Options
About this article
Cite this article as:
Zhao Jie, Huang Qi-Long, Tang Yue-Hua, Zhao Fu-Kun and Feng You-Min, In Vitro Unfolding of Insulin: Characterization of Intermediates and Putative Unfolding Pathway, Protein & Peptide Letters 2010; 17 (7) . https://dx.doi.org/10.2174/092986610791306724
DOI https://dx.doi.org/10.2174/092986610791306724 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prevention and Management of Ovarian Hyperstimulation Syndrome
Current Women`s Health Reviews Bioactive Proteins and Peptides from Soybeans
Recent Patents on Food, Nutrition & Agriculture Meet Our Co-Editor:
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Combined Cancer Therapy with Non-Conventional Drugs: All Roads Lead to AMPK
Mini-Reviews in Medicinal Chemistry Increased Circulatory Extrarenal 1α,25-Dihydroxyvitamin D3 in Bilaterally Nephrectomized Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets Type 1 Diabetes and Physical Exercise: Moving (forward) as an Adjuvant Therapy
Current Pharmaceutical Design Cytochrome P450 Turnover: Regulation of Synthesis and Degradation, Methods for Determining Rates, and Implications for the Prediction of Drug Interactions
Current Drug Metabolism Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers
Current Pharmaceutical Design HSF1 as a Cancer Biomarker and Therapeutic Target
Current Cancer Drug Targets Liver X Receptor: Crosstalk Node for the Signaling of Lipid Metabolism,Carbohydrate Metabolism, and Innate Immunity
Current Signal Transduction Therapy Imatinib Mesylate: An Innovation in Treatment of Autoimmune Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Genetic Risk Factors for Type 2 Diabetes: Insights from the Emerging Genomic Evidence
Current Vascular Pharmacology Insulin and the Blood-Brain Barrier
Current Pharmaceutical Design Emulsomes Meet S-layer Proteins: An Emerging Targeted Drug Delivery System
Current Pharmaceutical Biotechnology Pharmacotherapy of Dilated Cardiomyopathy
Current Pharmaceutical Design Organic Cation Transporters: Physiology, Toxicology and Special Focus on Ethidium as a Novel Substrate
Current Drug Metabolism High Glucose-Mediated Imbalance of Nitric Oxide Synthase and Dimethylarginine Dimethylaminohydrolase Expression in Endothelial Cells
Current Neurovascular Research Towards Standardized Stem Cell Therapy in Type 2 Diabetes Mellitus: A Systematic Review
Current Stem Cell Research & Therapy Diabetes Mellitus, Arterial Stiffness and Cardiovascular Disease: Clinical Implications and the Influence of SGLT2i
Current Vascular Pharmacology Poly-Electrolyte Complex: A Novel System for Biomedical Applications and Recent Patents
Recent Patents on Nanotechnology